Cinnamaldehyde and its combination with deferoxamine ameliorate inflammation, ferroptosis and hematoma expansion after intracerebral hemorrhage in mice

Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damag...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroinflammation Vol. 22; no. 1; pp. 45 - 20
Main Authors Liu, Yulin, Yang, Guoqiang, Liu, Mengnan, Zhang, Yuwei, Xu, Houping, Mazhar, Maryam
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 21.02.2025
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.
AbstractList Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNF[alpha], IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model. Keywords: Intracerebral hemorrhage, Brain injury, Inflammation, Oxidative stress, Lipid peroxidation, Ferroptosis, Hematoma clearance, Cluster of differentiation, Antioxidant, Neuroprotection, Cinnamaldehyde, Deferoxamine
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.
Abstract Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNFα, IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available. The underlying mechanisms driving brain injury are complex and include inflammation, oxidative stress, glutamate excitotoxicity, membrane damage, lipid peroxidation, ferroptosis and other cellular death modes. Hematoma clearance is the key to limit brain damage and foster the recovery process. The quest for effective ICH remedies is continuing and strategically evolving with the expansion of knowledge and understanding of target mechanisms and novel lead compounds. In this study, we have investigated the effects of cinnamaldehyde after ICH as an individual treatment as well as in combination with deferoxamine. The autologous blood injection model was employed using C57BL/6 mice. Following 2 h of ICH induction, animals received IP injection once per day for three days; normal saline in ICH model group, cinnamaldehyde, deferoxamine, and combined cinnamaldehyde and deferoxamine in respective groups. Measurement of neurobehavioral scoring, markers of inflammation NFкB, TNF[alpha], IL-1, IL6, iNOS; oxidative stress and ferroptosis GSH, TBARS, glutamate, choline containing phospholipids, GPX4, SLC7A11, SLC40A1, ACSL4; and hematoma clearance hemoglobin, haptoglobin, hemopexin, zonulin, CD163, LRP1, HO1, CD36, CD206, were investigated using ELISA, PCR, and western blot. Immunofluorescence for NeuN/SLC40A1, GFAP/GPX4, NeuN/HO1, Iba1/HO1 was also performed. We have found that cinnamaldehyde possess anti-inflammatory, antioxidant, anti-ferroptotic and hematoma limiting properties that were comparable to those obtained with deferoxamine. However, combination of cinnamaldehyde and deferoxamine demonstrated remarkable effectiveness in restoration of these parameters indicating their synergistic effect in ICH model.
ArticleNumber 45
Audience Academic
Author Yang, Guoqiang
Mazhar, Maryam
Xu, Houping
Liu, Yulin
Zhang, Yuwei
Liu, Mengnan
Author_xml – sequence: 1
  givenname: Yulin
  surname: Liu
  fullname: Liu, Yulin
– sequence: 2
  givenname: Guoqiang
  surname: Yang
  fullname: Yang, Guoqiang
– sequence: 3
  givenname: Mengnan
  surname: Liu
  fullname: Liu, Mengnan
– sequence: 4
  givenname: Yuwei
  surname: Zhang
  fullname: Zhang, Yuwei
– sequence: 5
  givenname: Houping
  surname: Xu
  fullname: Xu, Houping
– sequence: 6
  givenname: Maryam
  surname: Mazhar
  fullname: Mazhar, Maryam
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39985048$$D View this record in MEDLINE/PubMed
BookMark eNptkstu1DAUhiNURC_wAixQJDYsSPEttrNCVcWlUiU2sLZO4uMZV4k92BnoPAmvizNTqo6EvIhjf_7k4_OfVychBqyq15RcUqrlh0xZp0RDWNsQzhVvds-qM6oEaxjpxMmT-Wl1nvMdIZy1kr2oTnnX6ZYIfVb9ufYhwASjxfXOYg3B1n7O9RCn3geYfQz1bz-va4sOU7yHyYdCTTj6mGDG2gc3wjTtyfd1YVLczDH7vFetsezECWq830DIiw3cjKkcmxMMmLBPMC5YTGkNq8VXT37Al9VzB2PGVw_fi-rH50_fr782t9--3Fxf3TaD0GpuLHLOW6ta0Vmqeq0tE1xQqbgkqNwgiCRE09bRQbRApeCadw6VJoKplip-Ud0cvDbCndkkP0HamQje7BdiWhlIsx9GNEVge02YA2UF6_sOLBkkOMFd15ff4vp4cG22_YR2wKXG8Uh6vBP82qziL1O6KaQo7bmo3j0YUvy5xTybyecBxxECxm02nMquJVIyXtC3B3QF5W6lC3F50AU3V5rpYutoW6jL_1BlWCyvXOLkfFk_OvDmaQ2Pl_-XmAKwAzCkmHNC94hQshQizSGWpsTS7GNpdvwvlhLXpw
Cites_doi 10.1016/S2214-109X(13)70089-5
10.1016/j.cell.2012.03.042
10.1371/journal.pone.0193615
10.1002/acn3.485
10.1111/jnc.12974
10.1038/sigtrans.2017.23
10.3390/ijms23147977
10.1002/ctm2.965
10.1126/science.7100929
10.1016/S1474-4422(24)00369-7
10.1161/STROKEAHA.109.569830
10.1007/s007020070051
10.3171/jns.2004.100.4.0672
10.1007/s00109-013-1007-3
10.1161/STROKEAHA.115.011956
10.1016/j.mam.2020.100851
10.1182/blood-2005-03-1185
10.1523/JNEUROSCI.3776-09.2009
10.1016/S1474-4422(19)30069-9
10.1021/acsbiomaterials.2c00236
10.1016/j.lfs.2023.121814
10.1155/2020/10343252020
10.1111/cns.13399
10.1161/STROKEAHA.121.037298
10.1080/01480545.2017.1417995
10.1038/nchembio.2239
10.1016/j.brainres.2019.146514
10.14800/ttnd.474
10.1055/s-0036-1582132
10.1111/bph.13270
10.3389/fphys.2014.00415
10.1007/s11011-019-00480-7
10.1016/j.jtha.2024.06.028
10.1093/brain/123.10.2046
10.1080/01616412.1997.11740874
10.1161/CIRCRESAHA.121.319949
10.1016/j.wneu.2021.06.117
10.7554/eLife.35316
10.1016/j.plipres.2022.101207
10.1016/j.bbadis.2021.166204
10.1038/s41572-023-00424-7
10.1038/s41580-020-00324-8
10.1186/1742-2094-10-27
10.1155/2013/523652
10.1016/j.phymed.2024.155791
10.5853/jos.2016.00864
10.3390/ijms222111313
10.1016/S1474-4422(09)70340-0
10.1038/s41420-021-00553-6
10.1089/ars.2012.4834
10.1016/j.pharmthera.2023.108373
10.1038/s41420-024-02049-5
10.1080/21688370.2016.1251384
10.1016/S1474-4422(12)70104-7
10.1111/j.1749-6632.2010.05735.x
10.1172/jci.insight.90777
10.1097/01.WCB.0000073905.87928.6D
10.3390/molecules24081583
10.1016/j.expneurol.2019.05.003
10.12688/f1000research.20510.1
10.1213/ANE.0b013e3181d568c8
10.1038/jcbfm.2010.209
10.1016/j.bbr.2014.01.052
10.1007/s00701-010-0750-2
10.1161/STROKEAHA.110.596718
10.1016/j.cmet.2015.09.006
10.1111/acel.13235
10.1038/s41418-020-00685-9
10.1007/s40828-022-00163-4
10.3390/biom11111615
10.1161/STROKEAHA.117.016850
10.1080/10408390902773052
10.1161/STROKEAHA.123.045194
10.1016/j.nbd.2017.03.016
10.1016/j.bbamcr.2019.118535
10.1111/jcmm.13441
10.1016/j.ejphar.2021.174622
ContentType Journal Article
Copyright 2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s12974-025-03373-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1742-2094
EndPage 20
ExternalDocumentID oai_doaj_org_article_45adb802fa7d42bb9ad0c6af43f9bbb9
PMC11846400
A828400915
39985048
10_1186_s12974_025_03373_y
Genre Journal Article
GeographicLocations China
United States
Newfoundland and Labrador
GeographicLocations_xml – name: China
– name: Newfoundland and Labrador
– name: United States
GroupedDBID ---
0R~
29L
2WC
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7X8
PPXIY
5PM
PJZUB
PUEGO
ID FETCH-LOGICAL-c487t-de3335d7549d17b88d2434167360e7fc40600815f1c45a1643839fe7804275173
IEDL.DBID DOA
ISSN 1742-2094
IngestDate Wed Aug 27 01:14:45 EDT 2025
Thu Aug 21 18:27:14 EDT 2025
Fri Jul 11 10:44:32 EDT 2025
Tue Jun 17 21:59:38 EDT 2025
Tue Jun 10 21:08:25 EDT 2025
Sat May 10 01:40:29 EDT 2025
Tue Jul 01 05:36:01 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Neuroprotection
Oxidative stress
Cinnamaldehyde
Cluster of differentiation
Hematoma clearance
Lipid peroxidation
Ferroptosis
Inflammation
Antioxidant
Brain injury
Intracerebral hemorrhage
Deferoxamine
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c487t-de3335d7549d17b88d2434167360e7fc40600815f1c45a1643839fe7804275173
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/45adb802fa7d42bb9ad0c6af43f9bbb9
PMID 39985048
PQID 3169506623
PQPubID 23479
PageCount 20
ParticipantIDs doaj_primary_oai_doaj_org_article_45adb802fa7d42bb9ad0c6af43f9bbb9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11846400
proquest_miscellaneous_3169506623
gale_infotracmisc_A828400915
gale_infotracacademiconefile_A828400915
pubmed_primary_39985048
crossref_primary_10_1186_s12974_025_03373_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-02-21
PublicationDateYYYYMMDD 2025-02-21
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-21
  day: 21
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of neuroinflammation
PublicationTitleAlternate J Neuroinflammation
PublicationYear 2025
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References U Lendeckel (3373_CR11) 2022; 8
C Sturgeon (3373_CR73) 2016; 4
L Puy (3373_CR25) 2023; 9
M Mazhar (3373_CR37) 2021; 7
SJ Dixon (3373_CR8) 2012; 149
P Garland (3373_CR65) 2016; 47
Q Li (3373_CR49) 2017; 2
A di Masi (3373_CR63) 2020; 73
T Liu (3373_CR31) 2017; 2
S Javaid (3373_CR44) 2021
PR Krafft (3373_CR22) 2014; 264
H Fang (3373_CR32) 2013; 10
X Zhao (3373_CR10) 2009; 40
H Wu (3373_CR14) 2011; 31
A Etzerodt (3373_CR67) 2013; 18
VL Feigin (3373_CR1) 2024; 23
KR Wagner (3373_CR7) 2003; 23
M Roy-O’Reilly (3373_CR68) 2017; 4
M Błaż (3373_CR72) 2024
S Doll (3373_CR54) 2017; 13
V Hvidberg (3373_CR61) 2005; 106
R Liu (3373_CR71) 2017; 48
K Sahebi (3373_CR79) 2024; 10
Y Liu (3373_CR23) 2020; 26
3373_CR58
M Selim (3373_CR28) 2019; 18
JH Thomsen (3373_CR64) 2013; 2013
X Zhao (3373_CR60) 2009; 29
B Gürer (3373_CR20) 2019; 34
PW Pires (3373_CR27) 2018; 7
SJ An (3373_CR2) 2017; 19
MH Askenase (3373_CR30) 2016; 36
S Hu (3373_CR69) 2019; 318
X Jiang (3373_CR45) 2021; 22
X Diao (3373_CR40) 2020; 1727
M Selim (3373_CR12) 2009; 40
M Hajinejad (3373_CR17) 2020
CM Stuart (3373_CR75) 2022; 12
WM Clark (3373_CR21) 1997; 19
DM Feeney (3373_CR24) 1982; 217
X Zhao (3373_CR59) 2015; 133
J Aronowski (3373_CR9) 2011; 42
M Okauchi (3373_CR13) 2010; 41
OA Harari (3373_CR33) 2010; 1207
S Yan (3373_CR55) 2024; 132
RF Keep (3373_CR6) 2012; 11
YW Kim (3373_CR35) 2013; 91
G Wang (3373_CR66) 2018; 22
H Drakesmith (3373_CR51) 2015; 22
H Cheng (3373_CR56) 2021; 1867
J Magid-Bernstein (3373_CR26) 2022; 130
RV Krishnamurthi (3373_CR3) 2013; 1
L Foster (3373_CR15) 2022; 53
M Dorri (3373_CR47) 2018; 41
J Gruenwald (3373_CR16) 2010; 50
I Costa (3373_CR57) 2023; 244
L Zeng (3373_CR29) 2018; 13
3373_CR38
DJ Schaer (3373_CR62) 2014; 5
3373_CR34
WD Bao (3373_CR52) 2021; 28
3373_CR76
J Zhao (3373_CR18) 2015; 172
CJ van Asch (3373_CR4) 2010; 9
P Kuru Bektaşoğlu (3373_CR19) 2021; 153
D Galaris (3373_CR36) 2019; 1866
G Wang (3373_CR77) 2011; 153
J Fang (3373_CR53) 2021; 913
3373_CR39
CF Chang (3373_CR78) 2017; 103
AM Astudillo (3373_CR46) 2023; 89
T Nakamura (3373_CR48) 2004; 100
3373_CR74
MR Garnett (3373_CR43) 2000; 123
X Zhao (3373_CR70) 2024; 55
J Klein (3373_CR42) 2000; 107
J Elliott (3373_CR5) 2010; 110
D Neves (3373_CR41) 2023; 328
WD Bao (3373_CR50) 2020; 19
References_xml – volume: 40
  start-page: S90
  issue: 3suppl1
  year: 2009
  ident: 3373_CR12
  publication-title: Stroke
– volume: 1
  start-page: e259
  issue: 5
  year: 2013
  ident: 3373_CR3
  publication-title: Lancet Global Health
  doi: 10.1016/S2214-109X(13)70089-5
– volume: 149
  start-page: 1060
  issue: 5
  year: 2012
  ident: 3373_CR8
  publication-title: Cell
  doi: 10.1016/j.cell.2012.03.042
– volume: 13
  start-page: e0193615
  issue: 3
  year: 2018
  ident: 3373_CR29
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0193615
– volume: 4
  start-page: 793
  issue: 11
  year: 2017
  ident: 3373_CR68
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.485
– volume: 133
  start-page: 144
  issue: 1
  year: 2015
  ident: 3373_CR59
  publication-title: J Neurochem
  doi: 10.1111/jnc.12974
– volume: 2
  start-page: 17023
  year: 2017
  ident: 3373_CR31
  publication-title: Signal Transduct Target Therapy
  doi: 10.1038/sigtrans.2017.23
– ident: 3373_CR34
  doi: 10.3390/ijms23147977
– volume: 12
  start-page: e965
  issue: 7
  year: 2022
  ident: 3373_CR75
  publication-title: Clin Translational Med
  doi: 10.1002/ctm2.965
– volume: 217
  start-page: 855
  issue: 4562
  year: 1982
  ident: 3373_CR24
  publication-title: Sci (New York NY)
  doi: 10.1126/science.7100929
– volume: 23
  start-page: 973
  issue: 10
  year: 2024
  ident: 3373_CR1
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(24)00369-7
– volume: 41
  start-page: 375
  issue: 2
  year: 2010
  ident: 3373_CR13
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.109.569830
– volume: 107
  start-page: 1027
  issue: 8–9
  year: 2000
  ident: 3373_CR42
  publication-title: J Neural Transmission (Vienna Austria: 1996)
  doi: 10.1007/s007020070051
– volume: 100
  start-page: 672
  issue: 4
  year: 2004
  ident: 3373_CR48
  publication-title: J Neurosurg
  doi: 10.3171/jns.2004.100.4.0672
– volume: 91
  start-page: 323
  issue: 3
  year: 2013
  ident: 3373_CR35
  publication-title: J Mol Med
  doi: 10.1007/s00109-013-1007-3
– volume: 47
  start-page: 872
  issue: 3
  year: 2016
  ident: 3373_CR65
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.115.011956
– volume: 73
  start-page: 100851
  year: 2020
  ident: 3373_CR63
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2020.100851
– volume: 106
  start-page: 2572
  issue: 7
  year: 2005
  ident: 3373_CR61
  publication-title: Blood
  doi: 10.1182/blood-2005-03-1185
– volume: 29
  start-page: 15819
  issue: 50
  year: 2009
  ident: 3373_CR60
  publication-title: J Neuroscience: Official J Soc Neurosci
  doi: 10.1523/JNEUROSCI.3776-09.2009
– volume: 18
  start-page: 428
  issue: 5
  year: 2019
  ident: 3373_CR28
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(19)30069-9
– ident: 3373_CR58
  doi: 10.1021/acsbiomaterials.2c00236
– volume: 328
  start-page: 121814
  year: 2023
  ident: 3373_CR41
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2023.121814
– year: 2020
  ident: 3373_CR17
  publication-title: Biomed Res Int
  doi: 10.1155/2020/10343252020
– volume: 26
  start-page: 1031
  issue: 10
  year: 2020
  ident: 3373_CR23
  publication-title: CNS Neurosci Ther
  doi: 10.1111/cns.13399
– volume: 53
  start-page: 2204
  issue: 7
  year: 2022
  ident: 3373_CR15
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.121.037298
– volume: 41
  start-page: 338
  issue: 3
  year: 2018
  ident: 3373_CR47
  publication-title: Drug Chem Toxicol
  doi: 10.1080/01480545.2017.1417995
– volume: 13
  start-page: 91
  issue: 1
  year: 2017
  ident: 3373_CR54
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.2239
– volume: 1727
  start-page: 146514
  year: 2020
  ident: 3373_CR40
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2019.146514
– ident: 3373_CR76
  doi: 10.14800/ttnd.474
– volume: 36
  start-page: 288
  issue: 3
  year: 2016
  ident: 3373_CR30
  publication-title: Semin Neurol
  doi: 10.1055/s-0036-1582132
– volume: 172
  start-page: 5009
  issue: 20
  year: 2015
  ident: 3373_CR18
  publication-title: Br J Pharmacol
  doi: 10.1111/bph.13270
– volume: 5
  start-page: 415
  year: 2014
  ident: 3373_CR62
  publication-title: Front Physiol
  doi: 10.3389/fphys.2014.00415
– volume: 34
  start-page: 1737
  issue: 6
  year: 2019
  ident: 3373_CR20
  publication-title: Metab Brain Dis
  doi: 10.1007/s11011-019-00480-7
– volume: 40
  start-page: S92
  issue: 3suppl1
  year: 2009
  ident: 3373_CR10
  publication-title: Stroke
– year: 2024
  ident: 3373_CR72
  publication-title: J Thromb Haemost
  doi: 10.1016/j.jtha.2024.06.028
– volume: 123
  start-page: 2046
  issue: Pt 10
  year: 2000
  ident: 3373_CR43
  publication-title: Brain
  doi: 10.1093/brain/123.10.2046
– volume: 19
  start-page: 641
  issue: 6
  year: 1997
  ident: 3373_CR21
  publication-title: Neurol Res
  doi: 10.1080/01616412.1997.11740874
– volume: 130
  start-page: 1204
  issue: 8
  year: 2022
  ident: 3373_CR26
  publication-title: Circul Res
  doi: 10.1161/CIRCRESAHA.121.319949
– volume: 153
  start-page: e392
  year: 2021
  ident: 3373_CR19
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2021.06.117
– volume: 7
  start-page: e35316
  year: 2018
  ident: 3373_CR27
  publication-title: eLife
  doi: 10.7554/eLife.35316
– volume: 89
  start-page: 101207
  year: 2023
  ident: 3373_CR46
  publication-title: Prog Lipid Res
  doi: 10.1016/j.plipres.2022.101207
– volume: 1867
  start-page: 166204
  issue: 12
  year: 2021
  ident: 3373_CR56
  publication-title: Biochim et Biophys acta Mol Basis Disease
  doi: 10.1016/j.bbadis.2021.166204
– volume: 9
  start-page: 14
  issue: 1
  year: 2023
  ident: 3373_CR25
  publication-title: Nat Reviews Disease Primers
  doi: 10.1038/s41572-023-00424-7
– volume: 22
  start-page: 266
  issue: 4
  year: 2021
  ident: 3373_CR45
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-020-00324-8
– volume: 10
  start-page: 27
  year: 2013
  ident: 3373_CR32
  publication-title: J Neuroinflamm
  doi: 10.1186/1742-2094-10-27
– volume: 2013
  start-page: 523652
  year: 2013
  ident: 3373_CR64
  publication-title: Oxidative Med Cell Longev
  doi: 10.1155/2013/523652
– volume: 132
  start-page: 155791
  year: 2024
  ident: 3373_CR55
  publication-title: Phytomedicine: Int J Phytotherapy Phytopharmacology
  doi: 10.1016/j.phymed.2024.155791
– volume: 19
  start-page: 3
  issue: 1
  year: 2017
  ident: 3373_CR2
  publication-title: J Stroke
  doi: 10.5853/jos.2016.00864
– year: 2021
  ident: 3373_CR44
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms222111313
– volume: 9
  start-page: 167
  issue: 2
  year: 2010
  ident: 3373_CR4
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(09)70340-0
– volume: 7
  start-page: 149
  issue: 1
  year: 2021
  ident: 3373_CR37
  publication-title: Cell Death Discovery
  doi: 10.1038/s41420-021-00553-6
– volume: 18
  start-page: 2352
  issue: 17
  year: 2013
  ident: 3373_CR67
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2012.4834
– volume: 244
  start-page: 108373
  year: 2023
  ident: 3373_CR57
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2023.108373
– volume: 10
  start-page: 321
  issue: 1
  year: 2024
  ident: 3373_CR79
  publication-title: Cell Death Discovery
  doi: 10.1038/s41420-024-02049-5
– volume: 4
  start-page: e1251384
  issue: 4
  year: 2016
  ident: 3373_CR73
  publication-title: Tissue Barriers
  doi: 10.1080/21688370.2016.1251384
– volume: 11
  start-page: 720
  issue: 8
  year: 2012
  ident: 3373_CR6
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(12)70104-7
– volume: 1207
  start-page: 32
  year: 2010
  ident: 3373_CR33
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.2010.05735.x
– volume: 2
  start-page: e90777
  issue: 7
  year: 2017
  ident: 3373_CR49
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.90777
– volume: 23
  start-page: 629
  issue: 6
  year: 2003
  ident: 3373_CR7
  publication-title: J Cereb Blood flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism
  doi: 10.1097/01.WCB.0000073905.87928.6D
– ident: 3373_CR38
  doi: 10.3390/molecules24081583
– volume: 318
  start-page: 244
  year: 2019
  ident: 3373_CR69
  publication-title: Exp Neurol
  doi: 10.1016/j.expneurol.2019.05.003
– ident: 3373_CR74
  doi: 10.12688/f1000research.20510.1
– volume: 110
  start-page: 1419
  issue: 5
  year: 2010
  ident: 3373_CR5
  publication-title: Anesth Analg
  doi: 10.1213/ANE.0b013e3181d568c8
– volume: 31
  start-page: 1243
  issue: 5
  year: 2011
  ident: 3373_CR14
  publication-title: J Cereb Blood flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism
  doi: 10.1038/jcbfm.2010.209
– volume: 264
  start-page: 151
  year: 2014
  ident: 3373_CR22
  publication-title: Behav Brain Res
  doi: 10.1016/j.bbr.2014.01.052
– volume: 153
  start-page: 319
  issue: 2
  year: 2011
  ident: 3373_CR77
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-010-0750-2
– volume: 42
  start-page: 1781
  issue: 6
  year: 2011
  ident: 3373_CR9
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.110.596718
– volume: 22
  start-page: 777
  issue: 5
  year: 2015
  ident: 3373_CR51
  publication-title: Cell Metabol
  doi: 10.1016/j.cmet.2015.09.006
– volume: 19
  start-page: e13235
  issue: 11
  year: 2020
  ident: 3373_CR50
  publication-title: Aging Cell
  doi: 10.1111/acel.13235
– volume: 28
  start-page: 1548
  issue: 5
  year: 2021
  ident: 3373_CR52
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-020-00685-9
– volume: 8
  start-page: 12
  issue: 2
  year: 2022
  ident: 3373_CR11
  publication-title: Chemtexts
  doi: 10.1007/s40828-022-00163-4
– ident: 3373_CR39
  doi: 10.3390/biom11111615
– volume: 48
  start-page: 1369
  issue: 5
  year: 2017
  ident: 3373_CR71
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.117.016850
– volume: 50
  start-page: 822
  issue: 9
  year: 2010
  ident: 3373_CR16
  publication-title: Crit Rev Food Sci Nutr
  doi: 10.1080/10408390902773052
– volume: 55
  start-page: 166
  issue: 1
  year: 2024
  ident: 3373_CR70
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.123.045194
– volume: 103
  start-page: 54
  year: 2017
  ident: 3373_CR78
  publication-title: Neurobiol Dis
  doi: 10.1016/j.nbd.2017.03.016
– volume: 1866
  start-page: 118535
  issue: 12
  year: 2019
  ident: 3373_CR36
  publication-title: Biochim et Biophys acta Mol cell Res
  doi: 10.1016/j.bbamcr.2019.118535
– volume: 22
  start-page: 768
  issue: 2
  year: 2018
  ident: 3373_CR66
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.13441
– volume: 913
  start-page: 174622
  year: 2021
  ident: 3373_CR53
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2021.174622
SSID ssj0032562
Score 2.4476595
Snippet Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available....
Abstract Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 45
SubjectTerms Acrolein - administration & dosage
Acrolein - analogs & derivatives
Acrolein - therapeutic use
Aldehydes
Analysis
Animals
Antioxidants
Blood lipids
Brain
Brain damage
Brain injury
Care and treatment
Cell death
Cerebral Hemorrhage - complications
Cerebral Hemorrhage - drug therapy
Cerebral Hemorrhage - metabolism
Cerebral Hemorrhage - pathology
Deferoxamine
Deferoxamine - administration & dosage
Deferoxamine - therapeutic use
Diagnosis
Dosage and administration
Drug Therapy, Combination
Enzyme-linked immunosorbent assay
Ferroptosis
Ferroptosis - drug effects
Ferroptosis - physiology
Glutamate
Haptoglobin
Health aspects
Hematoma
Hematoma - drug therapy
Hematoma - etiology
Hematoma - pathology
Hemoglobin
Inflammation
Inflammation - drug therapy
Inflammation - etiology
Injuries
Intracerebral hemorrhage
Lipid peroxidation
Male
Membrane lipids
Mice
Mice, Inbred C57BL
Oxidative stress
Oxidative Stress - drug effects
Siderophores - administration & dosage
Title Cinnamaldehyde and its combination with deferoxamine ameliorate inflammation, ferroptosis and hematoma expansion after intracerebral hemorrhage in mice
URI https://www.ncbi.nlm.nih.gov/pubmed/39985048
https://www.proquest.com/docview/3169506623
https://pubmed.ncbi.nlm.nih.gov/PMC11846400
https://doaj.org/article/45adb802fa7d42bb9ad0c6af43f9bbb9
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtCqWX0nfcposKhR5aEVuSLfmYhIRQSCilgb0JyZLZhV072A5kf0n_bmfk3bCmh156tCXbsubTPGzNN4R8FkqXtqwdS52tmRReM10Iy-oy-NRW0lYWE4WvrovLG_l9ns_3Sn3hnrCRHnicuGOZW-90ymurvOTOldanVWFrKerSwSFqX7B5u2Bq1MECDDnfpcjo4rgHq6Ykw9KtqRBKsM3EDEW2_r918p5Rmm6Y3LNAFy_I863rSE_GIb8kj0Lzijy92v4cf01-ny2bxq7tyofFxgdqG0-XQ08BUxD-RglQ_OxKPZLLtvd2DZdRuw4rTNMfAgWwAT7GXMZvFPp07e3Q9ss-3iqyu7ZrS8M9aBD8yEZjgXG4DEZbhQ5_Qa-wW9t1C1BT0ECx2P0bcnNx_uvskm3rLrAKwpeB-SCEyL2C0NFnymntuQRjhzvA0qDqCnwA9CTyOqtAOhBvQZRb1gGpjLjKMyXekoOmbcIhoRneIOMhOGelCs6KSjtuC3AyeShCkZCvOzGY25Few8SwRBdmFJoBoZkoNLNJyClK6qEnUmPHEwAYswWM-RdgEvIF5WxwAeP02G0eAgwYqbDMCcSgoNjKLE_I0aQnLLxq0vxphxSDTbhbrQntXW9EVpQ5UuuLhLwbkfMwZnAIdQ5qMyF6gqnJS01bmuUi8n7DrMgCnv3-f0zDB_KMx_XAGc-OyMHQ3YWP4F8NbkYeq7makSen59c_fs7iwvoDRDErbg
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cinnamaldehyde+and+its+combination+with+deferoxamine+ameliorate+inflammation%2C+ferroptosis+and+hematoma+expansion+after+intracerebral+hemorrhage+in+mice&rft.jtitle=Journal+of+neuroinflammation&rft.au=Liu%2C+Yulin&rft.au=Yang%2C+Guoqiang&rft.au=Liu%2C+Mengnan&rft.au=Zhang%2C+Yuwei&rft.date=2025-02-21&rft.issn=1742-2094&rft.eissn=1742-2094&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12974-025-03373-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12974_025_03373_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon